Every two years, the MS International Federation awards the Charcot Award, recognizing lifetime achievement in outstanding research into the understanding and treatment of MS. My special guest is this year's recipient of the Charcot Award, Professor Alan Thompson, who is being honored for what is truly a remarkable body of work.
We'll also share some encouraging news from the FDA about a biomarker for progressive MS clinical trials.
We'll tell you about the outcome of a study that shows high-efficacy disease-modifying therapies lead to less disability over time for people with relapsing-remitting MS.
And we'll give you the details about how you can participate in a clinical trial that's comparing the safety, efficacy, and cost-effectiveness of autologous hematopoietic stem cell therapy (aHSCT) with high-efficacy disease-modifying therapies.
We have a lot to talk about! Are you ready for RealTalk MS??!
What the Charcot Award is all about :22
FDA supports further development of a biomarker for progressive MS clinical trials 2:10
Study shows high-efficacy DMTs lead to less disability over time 5:58
Recruitment underway for clinical trial comparing stem cell therapy to high-efficacy disease-modifying therapies 9:13
This month's Can-Do MS programs help battle fatigue 12:12
My conversation with Professor Alan Thompson 14:39
Share this episode 31:33
Download the free RealTalk MS app 31:53
SHARE THIS EPISODE OF REALTALK MS
Just copy this link & paste it into your text or email: https://realtalkms.com/201
ADD YOUR VOICE TO THE CONVERSATION
I've always thought about the RealTalk MS podcast as a conversation. And this is your opportunity to join the conversation by sharing your feedback, questions, and suggestions for topics that we can discuss in future podcast episodes. Please shoot me an email or call the RealTalk MS Listener Hotline and share your thoughts!
Phone: (310) 526-2283
And don't forget to join us in the RealTalk MS Facebook group!
National MS Society COVID-19 Vaccine Guidance for People Living with MS
FDA Letter of Support to encourage the further use and study of neurofilament light chain as a biomarker for early clinical trials in progressive MS
STUDY: Long-Term Disability Trajectories in Relapsing Multiple Sclerosis Patients Treated with Early Intensive or Escalation Treatment Strategies https://journals.sagepub.com/doi/full/10.1177/17562864211019574
CanDo MS Program Information and Registration
Join the RealTalk MS Facebook Group
Download the RealTalk MS App for iOS
Download the RealTalk MS App for Android
Give RealTalk MS a rating and review
RealTalk MS Episode 201
Guest: Professor Alan Thompson
Tags: MS, MultipleSclerosis, MSResearch, MSSociety, RealTalkMS